Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05387564 · ClinicalTrials.gov registry record · NA

Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach

A NA study, sponsored by Nemours Children's Clinic.

Completed
Registry status
NA
Development phase
114
Enrollment target

NCT05387564 is a NA study that has completed, run by Nemours Children's Clinic. The registered enrollment target is 114 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05387564, a NA study, has completed, sponsored by Nemours Children's Clinic.

COMPLETED
Registry status
NA
Development phase
114 participants
Enrollment target

Study Summary

The hemoglobinopathy newborn screen (NBS) performed on all neonates in the U.S. allows for early life-saving medical care for infants with sickle cell disease (SCD), an autosomal recessive genetic disorder. Because of its detection method, the NBS incidentally reveals hemoglobinopathy traits including sickle cell trait (SCT). In an effort to uphold the rights of the newborn to their medical data and preserve autonomy in medical decision making, pediatric and genetic society guidelines recommend disclosure and documentation of SCT results during infancy. Despite this guidance, a large guideline-to-practice gap exists: SCT status is grossly under-documented in the pediatric electronic health record and few adults report knowing their SCT status despite universal screening. We plan to evaluate the effect of a toolkit of SCT Documentation and Disclosure (SCT-DD) strategies on documentation and disclosure of SCT by pediatric primary care providers in a 2-arm randomized interrupted time series trial.

Interventions

  • BEHAVIORAL SCT Documentation and Disclosure Toolkit (SCT-DD)

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2024-01-18
Est. Completion 2024-12-30
Phase NA

Sponsor

Nemours Children's Clinic

108 total trials

What the Registry Record Tells You About NCT05387564

The ClinicalTrials.gov registry entry for NCT05387564 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nemours Children's Clinic, which has 108 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SCT Documentation and Disclosure Toolkit (SCT-DD) is the first listed.

NCT05387564 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05387564 about?

NCT05387564 is a clinical study titled "Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach". The hemoglobinopathy newborn screen (NBS) performed on all neonates in the U.S. allows for early life-saving medical care for infants with sickle cell disease (SCD), an autosomal recessive genetic disorder. Because of its detection method, the NBS incidentally reveals hemoglobinopathy traits includi...

What is the current status of trial NCT05387564?

This trial is currently completed. It is a NA study. The enrollment target is 114 participants. The study started on 2024-01-18. Estimated completion is 2024-12-30.

What interventions are being tested in trial NCT05387564?

The interventions under investigation include: SCT Documentation and Disclosure Toolkit (SCT-DD) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05387564?

This trial is sponsored by Nemours Children's Clinic, which has 108 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.